Patents Examined by Timothy R Rozof
  • Fused heteroaromatic-aniline compounds for treatment of dermal disorders
    Patent number: 11542271
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the Compound is according to Formula (I): where X, R1, R2, R2a, R3, R3a, and R3b are as described herein.
    Type: Grant
    Filed: April 20, 2021
    Date of Patent: January 3, 2023
    Assignee: NFLECTION THERAPEUTICS, INC.
    Inventors: John Kincaid, Matthew Duncton
  • Isoquinoline sulfonyl chloride acid addition salts and method of manufacture thereof
    Patent number: 11535595
    Abstract: A compound, such as isoquinoline-6-sulfonyl chloride acid and/or addition salts thereof, may be useful as a manufacturing intermediate for an isoquinoline-6-sulfonamide compound. A method for manufacturing such compounds and/or or acid addition salts thereof, may involve subjecting 6-(benzylthio)isoquinoline to an oxidative chlorination reaction and/or reacting 6-aminoisoquinoline with a nitrite or nitrous acid ester, then with thionyl chloride, and then with an acid.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: December 27, 2022
    Assignee: D. WESTERN THERAPEUTICS INSTITUTE, INC.
    Inventors: Kengo Sumi, Ryohei Nakamura
  • Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
    Patent number: 11530184
    Abstract: The invention provides polymorphs of a compound of Formula (X): The invention also provided pharmaceutical compositions containing polymorphs of the compound and methods treating conditions in a subject by providing polymorphs of the compound.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: December 20, 2022
    Assignee: IMBRIA PHARMACEUTICALS, INC.
    Inventors: Neil Buckley, Dan Belmont, Sarah Bethune, Krista Diaz
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 11530223
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: December 20, 2022
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
    Patent number: 11530231
    Abstract: A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: December 20, 2022
    Assignee: Sumitomo Pharma Oncology, Inc.
    Inventors: Adam Siddiqui-Jain, Paul Flynn, Shuji Masumoto, Hiroaki Tanaka, Hirotaka Kurebayashi, Takahiko Hashizuka, Yuka Arikawa
  • Corroles for treating poxvirus infection
    Patent number: 11529332
    Abstract: Disclosed is a family of corroles for their use in the treatment of an infection by poxvirus.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: December 20, 2022
    Assignees: UNIVERSITE DE BOURGOGNE, NÉOVIRTECH SAS
    Inventors: Claude Gros, Franck Gallardo, Nicolas Desbois
  • Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors
    Patent number: 11524010
    Abstract: In one aspect, compounds and compositions that inhibit TXNIP expression and/or that lower hepatic glucose production and methods of identifying, making, and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with elevated TXNIP and/or elevated glucagon levels such as, for example, diabetes and associated disorders. Further provided are methods for treating hyperlipidemia or fatty liver disease, optionally associated with elevated TXNIP and/or elevated glucagon levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: July 13, 2021
    Date of Patent: December 13, 2022
    Assignees: SOUTHERN RESEARCH INSTITUTE, THE UAB RESEARCH FOUNDATION
    Inventors: Corinne E. Augelli-Szafran, Omar Moukha-Chafiq, Mark J. Suto, Anath Shalev, Lance Thielen, Junqin Chen, Gu Jing
  • Methods for treating diseases mediated by ERBB4-positive pro-inflammatory macrophages
    Patent number: 11524055
    Abstract: Provided herein are methods and compositions for treating disease-states associated with presence of increased number of ErbB4+ pro-inflammatory macrophages in a subject in need thereof. The methods include providing an activator of ErbB4 and administering a therapeutically effective amount of the activator to the subject. The compositions include an activator of ErbB4. In one embodiment, the activation of ErbB4 is Neuregulin-4.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: December 13, 2022
    Assignee: Children's Hospital Los Angeles
    Inventors: Mark R. Frey, Michael Schumacher
  • H3K27 demethylase inhibitors in pediatric and juvenile osteoporosis
    Patent number: 11524011
    Abstract: The present invention provides methods for manipulating epigenetic factors to treat pediatric or juvenile osteoporosis. Specifically, the present invention provides methods for the application of H3K27 demethylase inhibitors in pediatric or juvenile subjects with osteoporosis. Thus, the present invention provides methods of administration of the H3K27 demethylase inhibitor, GSK-J4, to pediatric or juvenile subjects to effectively inhibit primary and secondary pediatric osteoporosis, especially for long-term glucocorticoid treated patients (juvenile rheumatoid disorders, Crohn's disease, nephrotic syndrome, and Duchenne muscular dystrophy) and patients who have compromised mobility (cerebral palsy, Rett syndrome, Duchenne muscular dystrophy, spina bifida, and spinal muscular atrophy).
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: December 13, 2022
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Mei Wan, Xu Cao
  • Sulfonamide carboxamide compounds
    Patent number: 11518739
    Abstract: The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 is a saturated or unsaturated, optionally substituted C1-C15 hydrocarbyl group, wherein the atom of R1 which is attached to the sulfur atom of the sulfonylurea group is not a ring atom of a cyclic group; and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: December 6, 2022
    Assignee: INFLAZOME LIMITED
    Inventors: David Miller, Angus Macleod, Jimmy Van Wiltenburg, Stephen Thom, Stephen St-Gallay, Jonathan Shannon
  • Crystal of benzoxazole derivative
    Patent number: 11512091
    Abstract: Provided are crystals of 1-((2-(3,6-diazabicyclo[3.1.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: November 29, 2022
    Assignee: Meiji Seika Pharma Co., Ltd.
    Inventors: Ko Kumura, Keiji Tamura, Takashi Watanabe, Michiko Takahashi
  • Compound having cyclic structure
    Patent number: 11512067
    Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: A: e.g., Benzene, E: e.g., —CH2—, G: e.g., a 5-membered aromatic heterocyclic ring, X: e.g., cyclohexane, J: e.g., a 5-membered aromatic heterocyclic ring, Y: e.g., a phenyl group, R1, R2, R3: e.g., a halogen atom, R4: e.g., a C1-C6 alkyl group, R5: e.g., a hydrogen atom, R6a, R6b, R6c, R6d: e.g., a hydrogen atom, R7: e.g., a hydrogen atom, R8: e.g., a hydrogen atom, n1, n2, n3: e.g., 1.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: November 29, 2022
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Toru Taniguchi, Osamu Iwamoto, Keiji Saito, Katsuyoshi Nakajima, Yasuyuki Ogawa, Nobuya Kurikawa, Seiko Nagata, Kaori Ito, Eriko Kioi
  • 8-phenyl-isoquinolines and pharmaceutical composition thereof used in the treatment of irritable bowel syndrome
    Patent number: 11505529
    Abstract: A series of 8-phenyl-isoquinoline derivatives (I) exhibit high binding affinity to 5-HT7 receptor (5-HT7R) and demonstrate potent antinociceptive activity in two animal models for Irritable Bowel Syndrome (IBS) by intraperitoneal injection (i.p.) or by oral administration (p.o.). These 5-HT7 receptor antagonists are a new class of therapeutic agents for the treatment of IBS.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: November 22, 2022
    Assignee: NATIONAL TAIWAN UNIVERSITY
    Inventor: Linda Chia-Hui Yu
  • Process for the preparation of Cabozantinib and its pharmaceutically acceptable salts thereof
    Patent number: 11498902
    Abstract: The present invention relates to an improved process for the preparation of N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide compound of formula-1 which is represented by the following structural formula:
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: November 15, 2022
    Assignee: NATCO PHARMA LIMITED
    Inventors: Kompella Amala, Gampa Venugopala Krishna, Annadasu Ankamanayudu, Ganganamoni Srinivasulu, Konakanchi Durga Prasad, Muddasani Pulla Reddy, Nannapaneni Venkaiah Chowdary
  • TrkA Inhibitor
    Patent number: 11498915
    Abstract: The present invention relates to compound of the following structure for use as an inhibitor of TrkA, as well as compositions including this compound, and methods of using this compound for the treatment of pain including post-surgical pain, rheumatoid arthritis pain, neuropathic pain and osteoarthritis pain.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: November 15, 2022
    Assignee: ELI LILLY AND COMPANY
    Inventors: David A. Coates, Ryan James Linder, Laia Malet-Sanz
  • Piperidine-2,6-dione derivatives and ulcerative colitis treating
    Patent number: 11485724
    Abstract: Disclosed are piperidine-2,6-dione derivatives and treatment of ulcerative colitis.
    Type: Grant
    Filed: November 23, 2017
    Date of Patent: November 1, 2022
    Assignees: Tianjin Hemay Pharmaceutical Sci-Tech Co., Ltd, Ganzhou Hemay Pharmaceutical, Co., Ltd
    Inventors: Hesheng Zhang, Guanghuai Zeng
  • Anti-infective agents
    Patent number: 11485720
    Abstract: The present invention relates to a novel class of chromene-2-carboxamide compounds inhibitors of general formula I wherein R1, R2, R3, R4, R5, R6, R7, R8 and X are as defined herein, to their use in medicine, and their use as anti-infective agents in particular, to compositions containing them, to processes for their preparation and to intermediates used in such processes.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: November 1, 2022
    Assignee: UNIVERSITY OF DUNDEE
    Inventors: Barbara Forte, Neil Norcross, Chimed Jansen, Beatriz Baragana, Ian Gilbert, Laura Cleghorn, Susan Davis, Christopher Walpole
  • Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2C (5-HT)
    Patent number: 11485734
    Abstract: Disclosed are novel small molecules, methods of synthesis of the small molecules, and uses of the small molecules for modulating activity of the human serotonin receptor 2C (5-HT2c), preferably selectively. The small molecules have a substituted beta-carboline core structure, which optionally may be saturated at one or more bonds to provide a dihydro-beta-carboline core or a tetrahydro-beta-carboline core. The small molecules may be administered to treat and/or prevent diseases, disorders, and/or conditions associated with human serotonin receptor 2C (5-HT2C) including psychiatric, mental, and/or neurological diseases, disorders, and conditions such as cognitive impairment, addiction, and obsessive compulsive disorder. The disclosed small molecules also may be administered to treat and/or prevent obesity, for example, via appetite suppression.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: November 1, 2022
    Assignee: Northwestern University
    Inventors: Karl A. Scheidt, Herbert Y. Meltzer, Adam J. Csakai
  • Griseofulvin compound
    Patent number: 11472784
    Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: October 18, 2022
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Keiji Saito, Katsuyoshi Nakajima, Toru Taniguchi, Osamu Iwamoto, Satoshi Shibuya, Yasuyuki Ogawa, Kazumasa Aoki, Nobuya Kurikawa, Shinji Tanaka, Momoko Ogitani, Eriko Kioi, Kaori Ito, Natsumi Nishihama, Tsuyoshi Mikkaichi, Wataru Saitoh
  • Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts
    Patent number: 11472771
    Abstract: The present invention relates to a process for making a compound of formula (I) as described herein Formula (I) comprising reducing a compound of formula (II) as described herein with hydrogen in the presence of a palladium catalyst and a solvent wherein the solvent is a polar, aprotic solvent or a C3-C10 alcohol Formula (II). The present invention further relates to a hydrochloride salt and a monohydrochloride salt of the compound of formula (I) as described herein and to a process for making the same Formula (I).
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: October 18, 2022
    Assignee: CELLESTIA BIOTECH AG
    Inventors: Michael Bauer, Uwe Hahn, Erhard Bappert